Nuvectis Pharma Files 8-K on Security Holder Votes
Ticker: NVCT · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1875558
| Field | Detail |
|---|---|
| Company | Nuvectis Pharma, Inc. (NVCT) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: NUVT
TL;DR
Nuvectis Pharma (NUVT) filed an 8-K for shareholder votes. Keep an eye on governance.
AI Summary
Nuvectis Pharma, Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). Nuvectis Pharma, Inc. is a pharmaceutical preparations company based in Fort Lee, NJ.
Why It Matters
This filing indicates that Nuvectis Pharma is engaging its shareholders on important corporate matters, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not contain information about significant financial events or operational changes.
Key Players & Entities
- Nuvectis Pharma, Inc. (company) — Registrant
- June 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Fort Lee, NJ (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Nuvectis Pharma, Inc.?
The primary purpose of this 8-K filing is to report on the submission of matters to a vote of Nuvectis Pharma, Inc.'s security holders.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on June 13, 2024.
In which state is Nuvectis Pharma, Inc. incorporated?
Nuvectis Pharma, Inc. is incorporated in Delaware.
What is the address of Nuvectis Pharma, Inc.'s principal executive offices?
The address of Nuvectis Pharma, Inc.'s principal executive offices is 1 Bridge Plaza Suite 275 Fort Lee, NJ 07024.
What is Nuvectis Pharma, Inc.'s IRS Employer Identification No.?
Nuvectis Pharma, Inc.'s IRS Employer Identification No. is 86-2405608.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-06-13 16:09:21
Filing Documents
- tm2417208d1_8k.htm (8-K) — 27KB
- 0001104659-24-071261.txt ( ) — 196KB
- nvct-20240613.xsd (EX-101.SCH) — 3KB
- nvct-20240613_lab.xml (EX-101.LAB) — 33KB
- nvct-20240613_pre.xml (EX-101.PRE) — 22KB
- tm2417208d1_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On Thursday, June 13, 2024, at 10:00 a.m. Eastern Time, by means of an online meeting platform, the Company held its 2024 Annual Meeting. Stockholders representing 12,227,134, or 66.55%, of the 18,370,758 shares of common stock outstanding on the record date of April 15, 2024 were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. Each of the proposals below are described in detail in the Company's definitive proxy statement on Schedule 14A for the 2024 Annual Meeting, filed with the SEC on April 29, 2024. At the 2024 Annual Meeting, all of the proposals were approved. The results are as follows: Proposal 1 The votes with respect to the election of the Class II directors to hold office until the 2027 annual meeting were as follows: Director Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes Kenneth Hoberman 8,026,155 809,797 2,637 3,388,545 Matthew Kaplan 8,502,724 333,228 2,637 3,388,545 Proposal 2 The vote with respect to the ratification of Kesselman & Kesselman as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows: Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes 12,055,252 31,882 140,000 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvectis Pharma, Inc. (Registrant) Date: June 13, 2024 By: /s/ Ron Bentsur Ron Bentsur Chairman, Chief Executive Officer and President